Literature DB >> 16312269

A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism.

S Kursat1, T Alici, H B Colak.   

Abstract

Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle contents into the systemic circulation. We hereby report a patient proved to be a case of unrecognized hypothyroidism presenting with rhabdomyolytic acute renal failure precipitated by the combined use of statin and fenofibrate. A 63-year-old woman was referred to our department because of fatigue, diffuse muscle pain and oliguria. On the basis of pathogenesis, clinical and laboratory examination the diagnoses of acute renal failure secondary to the statin-fibrate-derivative combination induced rhabdomyolysis and auto-immune thyroiditis induced hypothyroidism were made. Although saline, furosemide and sodium bicarbonate infusions enabled diuresis and have led to a rapid recovery of renal function and normalization of blood pressure in five days (creatinine level decreased from 4.5 mg/dl to 1.2 mg/dl), only thyroid replacement therapy (0,1 mg thyroxine) that begun after the exclusion of adrenal insufficiency resulted in complete resolution of rhabdomyolysis. This prompted the diagnosis of background, clinically silent rhabdomyolysis aggrevated by the statin-fibrate-derivative combination. To our knowledge this case illustrates the first example of rhabdomyolytic acute renal failure induced by a statin-fibrate-derivative combination with underlying hypothyroidism which was responsible for the basal clinically unobservable rhabdomyolysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16312269     DOI: 10.5414/cnp64391

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

Review 1.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Serum myoglobin in patients with thyroid dysfunction.

Authors:  Waad-Allah S Mula-Abed; Sawsan S Al-Sinani; Huda S Al-Hashmi
Journal:  Sultan Qaboos Univ Med J       Date:  2009-03-16

3.  Severe rhabdomyolysis and acute renal failure secondary to the use of simvastatin in undiagnosed hypothyroidism.

Authors:  F A Qari
Journal:  Indian J Nephrol       Date:  2008-01

4.  Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.

Authors:  Ramazan Danis; Sami Akbulut; Sehmus Ozmen; Senay Arikan
Journal:  Case Rep Med       Date:  2010-07-25

Review 5.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Authors:  Elisavet Moutzouri; Anastazia Kei; Moses S Elisaf; Haralampos J Milionis
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

6.  Editorial: secondary dyslipidemias.

Authors:  Moses Elisaf; Vasilis Tsimihodimos
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

7.  Interactions between thyroid disorders and kidney disease.

Authors:  Gopal Basu; Anjali Mohapatra
Journal:  Indian J Endocrinol Metab       Date:  2012-03

8.  Statin-induced bilateral foot drop in a case of hypothyroidism.

Authors:  Neera Chaudhary; Ashish Kumar Duggal; Prashant Makhija; Vinod Puri; Geeta Anjum Khwaja
Journal:  Ann Indian Acad Neurol       Date:  2015 Jul-Sep       Impact factor: 1.383

9.  Rhabdomyolysis induced acute renal failure secondary to statins.

Authors:  R Ram; G Swarnalatha; V Ramesh; K Nageswar Rao; K V Dakshinamurty
Journal:  Indian J Nephrol       Date:  2013-05

Review 10.  Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

Authors:  Jianyong Wu; Yan Song; Heng Li; Jianghua Chen
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 3.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.